pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
onclive·May 15·1 min read
save

GU experts poll top abstract topics for ASCO 2026 meeting

May 15, 2026·read at onclive ↗Neutral

A poll of genitourinary oncology specialists was conducted to gauge interest in upcoming ASCO 2026 abstracts.

Participants used OncLive’s social media platform to nominate the abstracts they expect to be most impactful.

The results highlight which GU cancer areas are generating the most anticipation among the community.

This insight may help attendees prioritize sessions and guide presenters on topics of high relevance.

source

This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.

Original headline: “Poll Findings Highlight the Most Anticipated GU Cancer Abstracts at ASCO 2026”

read at onclive ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Oncology3Urology

related stories

  • 2d agoBreast cancer can behave differently in older women. This physician is making more tailored treatments a realitySTAT
  • Sep 11FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancerFierce Biotech
  • Aug 31A winner, a loser, and a mid-stage signal from a major cardiology research conferenceSTAT
  • Aug 21Scientists deploy Merck’s Ebola vaccine in DRCSTAT
  • Aug 21Focal therapy for localized prostate cancer has divided physicians. Will new data change minds?STAT